TY - JOUR
T1 - Case Discussion and Literature Review
T2 - Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
AU - Ragoonanan, Dristhi
AU - Khazal, Sajad J.
AU - Mejia, Rodrigo
AU - Ewing, Linette
AU - Durand, Jean Bernard
AU - Bashoura, Lara
AU - Tayar, Jean
AU - Dailey Garnes, Natalie
AU - Petropoulos, Demetrios
AU - Tewari, Priti
AU - Bhatti, Micah
AU - Ahmad, Ali Haider
AU - Cortes, Jose
AU - Razvi, Shehla
AU - McBeth, Katrina
AU - Swinford, Rita
AU - Shoberu, Basirat
AU - Waseemuddin, Waseem
AU - Chi, Linda
AU - Gill, Jonathan B.
AU - Zaky, Wafik
AU - Daw, Najat
AU - Gutierrez, Cristina
AU - Tereffe, Welela
AU - Kebriaei, Partow
AU - Rezvani, Katayoun
AU - Shpall, Elizabeth J.
AU - Champlin, Richard E.
AU - Mahadeo, Kris M.
N1 - Publisher Copyright:
© Copyright © 2021 Ragoonanan, Khazal, Mejia, Ewing, Durand, Bashoura, Tayar, Dailey Garnes, Petropoulos, Tewari, Bhatti, Ahmad, Cortes, Razvi, McBeth, Swinford, Shoberu, Waseemuddin, Chi, Gill, Zaky, Daw, Gutierrez, Tereffe, Kebriaei, Rezvani, Shpall, Champlin and Mahadeo.
PY - 2021/2/4
Y1 - 2021/2/4
N2 - Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.
AB - Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.
KW - COVID-19
KW - MIS-A
KW - MIS-C
KW - SARS-CoV-2
KW - cancer immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85101105185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101105185&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.625707
DO - 10.3389/fonc.2021.625707
M3 - Review article
C2 - 33614514
AN - SCOPUS:85101105185
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 625707
ER -